









市場行情
/
股票
/
nasdaq-lgnd
/

Ligand Pharmaceuticals Inc

LGND

191.240USD

-0.070-0.04%

收盤 11/03, 16:00（美東）報價延遲15分鐘

3.71B總市值

虧損本益比TTM



Ligand Pharmaceuticals Inc

191.240

-0.070-0.04%

概覽公司財務分析

概覽

公司

財務

分析

關於 Ligand Pharmaceuticals Inc 公司

Ligand Pharmaceuticals Incorporated 是一家生物製藥公司，通過支持藥物的臨牀開發來推動科學進步。該公司通過提供融資、授權其技術或兩者兼而有之來實現這一目標。其 Captisol 平臺技術是一種化學改性環糊精，其結構旨在優化藥物的溶解度和穩定性。該技術已使多種美國食品藥品管理局 (FDA) 批准的產品成爲可能，包括吉利德的 Veklury、安進的 Kyprolis、百特國際的 Nexterone、Melinta Therapeutics 的 Baxdela 和 Sage Therapeutics 的 Zulresso。其技術還包括 HepDirect、LTP 和 BEPro 技術平臺、SUREtechnology 平臺（由 Selexis 擁有）和 Pelican Expression Technology。該公司已與安進、默克、輝瑞、Jazz、武田、吉利德科學和百特國際等多家制藥公司建立了多個聯盟、許可和其他業務關係。

Ligand Pharmaceuticals Inc簡介



公司代碼LGND

公司名稱Ligand Pharmaceuticals Inc

上市日期Nov 18, 1992

CEOMr. Todd C. Davis

員工數量68

證券類型Ordinary Share

年結日Nov 18

公司地址555 Heritage Drive, Suite 200

城市JUPITER

上市交易所NASDAQ Global Market Consolidated

國家United States of America

郵編33458

電話18585507500

網址https://www.ligand.com/

公司代碼LGND

上市日期Nov 18, 1992

CEOMr. Todd C. Davis

Ligand Pharmaceuticals Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Jason M. Aryeh

Independent Director

127.16K

-7.29%

Dr. John W. Kozarich ,Ph.D.

Independent Chairman of the Board

43.90K

-1.05%

Dr. Stephen L. Sabba, M.D.

Independent Director

35.05K

+3.57%

Dr. John L. Lamattina, Ph.D.

Independent Director

31.98K

+3.93%

Mr. Andrew Reardon

Chief Legal Officer

15.72K

-7.77%

Mr. Octavio (Tavo) Espinoza

Chief Financial Officer

10.12K

+2.26%

Dr. Nancy Ryan Gray, Ph.D.

Independent Director

9.35K

+14.86%

Mr. Jason Haas

Independent Director

6.86K

+21.40%

Dr. Martine Zimmermann, Pharm.D.

Independent Director

4.17K

-2.68%

Mr. Todd C. Davis

Chief Executive Officer, Director

名稱

名稱/職務

職務

持股

持股變動

Mr. Jason M. Aryeh

Independent Director

127.16K

-7.29%

Dr. John W. Kozarich ,Ph.D.

Independent Chairman of the Board

43.90K

-1.05%

Dr. Stephen L. Sabba, M.D.

Independent Director

35.05K

+3.57%

Dr. John L. Lamattina, Ph.D.

Independent Director

31.98K

+3.93%

Mr. Andrew Reardon

Chief Legal Officer

15.72K

-7.77%

Mr. Octavio (Tavo) Espinoza

Chief Financial Officer

10.12K

+2.26%

收入明細

單位: USD更新時間: 10月6日週一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

業務USD

名稱

營收

佔比

Kyprolis

8.80M

18.48%

Captisol

8.29M

17.40%

Filspari

6.58M

13.81%

Qarziba

5.88M

12.36%

Royalties Other

5.43M

11.41%

其他

12.64M

26.54%

暫無數據

業務

地區

業務USD

名稱

營收

佔比

Kyprolis

8.80M

18.48%

Captisol

8.29M

17.40%

Filspari

6.58M

13.81%

Qarziba

5.88M

12.36%

Royalties Other

5.43M

11.41%

其他

12.64M

26.54%

股東統計

更新時間: 11月2日週日

持股股東

股東類型

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

13.55%

The Vanguard Group, Inc.

10.64%

Janus Henderson Investors

5.41%

Macquarie Investment Management

4.73%

State Street Investment Management (US)

3.83%

其他

61.85%

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

13.55%

The Vanguard Group, Inc.

10.64%

Janus Henderson Investors

5.41%

Macquarie Investment Management

4.73%

State Street Investment Management (US)

3.83%

其他

61.85%

股東類型

持股股東

佔比

Investment Advisor

58.05%

Investment Advisor/Hedge Fund

38.85%

Individual Investor

2.29%

Pension Fund

1.60%

Research Firm

1.26%

Bank and Trust

0.45%

Hedge Fund

0.45%

Sovereign Wealth Fund

0.10%

Venture Capital

0.04%

機構持股



更新時間: 10月5日週日

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

538

19.85M

101.27%

-443.72K

2025Q2

535

19.71M

102.13%

-738.05K

2025Q1

554

19.82M

102.82%

-711.89K

2024Q4

546

19.28M

100.16%

-1.51M

2024Q3

543

19.17M

104.83%

-583.22K

2024Q2

527

18.31M

101.74%

-865.78K

2024Q1

520

17.60M

99.35%

-393.03K

2023Q4

527

16.97M

97.29%

-861.76K

2023Q3

515

17.24M

99.38%

-910.17K

2023Q2

526

17.09M

98.94%

-1.02M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

BlackRock Institutional Trust Company, N.A.

2.65M

13.55%

-19.35K

-0.72%

Jun 30, 2025

The Vanguard Group, Inc.

2.08M

10.64%

+33.19K

+1.62%

Jun 30, 2025

Janus Henderson Investors

1.06M

5.41%

+33.19K

+3.23%

Jun 30, 2025

Macquarie Investment Management

926.55K

4.73%

+20.33K

+2.24%

Jun 30, 2025

State Street Investment Management (US)

749.75K

3.83%

+22.63K

+3.11%

Jun 30, 2025

Dimensional Fund Advisors, L.P.

704.52K

3.6%

-40.41K

-5.42%

Jun 30, 2025

Congress Asset Management Company, LLP

647.94K

3.31%

+5.23K

+0.81%

Jun 30, 2025

Chicago Capital, LLC

571.83K

2.92%

+17.31K

+3.12%

Jun 30, 2025

Stephens Investment Management Group, LLC

604.81K

3.09%

-2.41K

-0.40%

Jun 30, 2025

MFS Investment Management

339.74K

1.73%

+61.95K

+22.30%

Jun 30, 2025

持股ETF



更新時間: 11月2日週日

機構名稱

佔比

Franklin Genomic Advancements ETF

3.58%

Invesco Pharmaceuticals ETF

Virtus LifeSci Biotech Products ETF

2.58%

SPDR S&P Pharmaceuticals ETF

2.56%

Invesco S&P SmallCap Health Care ETF

2.21%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.92%

Pacer US Small Cap Cash Cows Growth Leaders ETF

1.73%

Invesco Dorsey Wright Healthcare Momentum ETF

1.65%

iShares U.S. Pharmaceuticals ETF

1.28%

OneAscent Small Cap Core ETF

0.97%

Franklin Genomic Advancements ETF

佔比3.58%

Invesco Pharmaceuticals ETF

佔比3%

Virtus LifeSci Biotech Products ETF

佔比2.58%

SPDR S&P Pharmaceuticals ETF

佔比2.56%

Invesco S&P SmallCap Health Care ETF

佔比2.21%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

佔比1.92%

Pacer US Small Cap Cash Cows Growth Leaders ETF

佔比1.73%

Invesco Dorsey Wright Healthcare Momentum ETF

佔比1.65%

iShares U.S. Pharmaceuticals ETF

佔比1.28%

OneAscent Small Cap Core ETF

佔比0.97%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

KeyAI

